Takeda bets $100M upfront on AC Immune’s anti-amyloid Alzheimer’s vaccine –

Takeda shutterstock social1


AC Im­mune has lined up its third phar­ma part­ner in Alzheimer’s dis­ease, and the pact comes with a hefty biobucks pack­age.

Take­da will pay AC Im­mune $100 mil­lion up­front to snag the ex­clu­sive op­tion to li­cense the Swiss biotech’s an­ti-amy­loid vac­cine, which is in Phase 1b/2 test­ing in the US and Eu­rope. If the drug­mak­er opts to fur­ther de­vel­op the im­munother­a­py, dubbed ACI-24.060, it could dish out up to an­oth­er $2.1 bil­lion in op­tion fees and mile­stones, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.



This article was originally published by a endpts.com

Read it HERE

Share

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *